7,290 XNAS Volume
XNAS 18 Mar, 2025 10:45 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Shane M. Ward | COO & CLO | Sale of securities on an exchange or to another person at price $ 21.96 per share. | 11 Mar 2025 | 1,664 | 14,674 (0%) | 0% | 22.0 | 36,542 | Common Stock |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 21.96 per share. | 11 Mar 2025 | 1,773 | 16,215 (0%) | 0% | 22.0 | 38,940 | Common Stock |
| Frank L. Karbe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 57,500 | 57,500 (0%) | 0% | 0 | Common Stock | |
| Frank L. Karbe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 115,000 | 115,000 | - | - | Employee Stock Option (right to buy) | |
| Burgess D. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Bonnie L. Bassler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Schroeder R. Theodore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Canale-Theakston Carin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 560,888 | 560,888 | - | - | Employee Stock Option (right to buy) | |
| Shane M. Ward | COO & CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 135,540 | 135,540 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 166,836 | 166,836 | - | - | Employee Stock Option (right to buy) | |
| Preetam Shah | Chief Financial Officer | 30 Sep 2024 | 130,087 | 130,087 | - | - | Employee Stock Option (right to buy) | ||
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 150,224 | 150,224 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.64 per share. | 11 Sep 2024 | 924 | 23,067 (0%) | 0% | 11.6 | 10,752 | Common Stock |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 11.64 per share. | 11 Sep 2024 | 909 | 17,788 (0%) | 0% | 11.6 | 10,580 | Common Stock |
| Daniel D. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Bonnie L. Bassler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Ryan Spencer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Carin Canale-Theakston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| James Merson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Laura Tadvalkar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 2,125 | 2,125 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 13.21 per share. | 07 Jun 2024 | 8,000 | 24,580 (0%) | 0% | 13.2 | 105,680 | Common Stock |
| Ryan Spencer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 4,250 | 4,250 | - | - | Stock Option (right to buy) | |
| James Merson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 4,250 | 4,250 | - | - | Stock Option (right to buy) | |
| Laura Tadvalkar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 4,250 | 4,250 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 1,040,000 | 1,040,000 | - | - | Employee Stock Option (right to buy) | |
| Shane M. Ward | COO & CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 120,000 | 318,770 (0%) | 0% | 0 | Common Stock | |
| Shane M. Ward | COO & CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 235,500 | 235,500 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 128,750 | 475,845 (1%) | 0% | 0 | Common Stock | |
| Preetam Shah | CFO & CBO | 15 Mar 2024 | 217,500 | 217,500 | - | - | Employee Stock Option (right to buy) | ||
| Preetam Shah | CFO & CBO | 15 Mar 2024 | 108,750 | 335,960 (0%) | 0% | 0 | Common Stock | ||
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 222,500 | 222,500 | - | - | Employee Stock Option (right to buy) | |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 111,250 | 369,931 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. | 11 Mar 2024 | 56,692 | 1,153,693 (2%) | 0% | 0.7 | 39,117 | Common Stock |
| Shane M. Ward | COO & CLO | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 11 Mar 2024 | 20,473 | 198,770 (0%) | 0% | 0.7 | 13,713 | Common Stock |
| Taylor Sandison | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 11 Mar 2024 | 20,662 | 347,095 (0%) | 0% | 0.7 | 13,839 | Common Stock |
| Preetam Shah | CFO & CBO | 11 Mar 2024 | 18,931 | 227,210 (0%) | 0% | 0.7 | 12,680 | Common Stock | |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 11 Mar 2024 | 21,029 | 258,681 (0%) | 0% | 0.7 | 14,085 | Common Stock |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 14 Aug 2023 | 10,000 | 294,179 (0%) | 0% | 1.0 | 9,700 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.96 per share. | 08 Aug 2023 | 50,000 | 331,602 (0%) | 0% | 1.0 | 47,885 | Common Stock |
| Daniel D. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Bonnie L. Bassler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| David L. Gollaher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Carin Canale-Theakston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 543,500 | 543,500 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.04 per share. | 27 Mar 2023 | 50,000 | 281,602 (0%) | 0% | 1.0 | 51,855 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 271,750 | 1,202,385 (2%) | 0% | 0 | Common Stock | |
| Shane M. Ward | COO & CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 126,667 | 211,243 (0%) | 0% | 0 | Common Stock | |
| Shane M. Ward | COO & CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 253,333 | 253,333 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 90,000 | 378,550 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| Preetam Shah | CFO & CBO | 27 Mar 2023 | 90,000 | 238,141 (0%) | 0% | 0 | Common Stock | ||
| Preetam Shah | CFO & CBO | 27 Mar 2023 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | ||
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 90,000 | 280,179 (0%) | 0% | 0 | Common Stock | |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| Shane M. Ward | COO & CLO | Sale of securities on an exchange or to another person at price $ 1.53 per share. | 13 Mar 2023 | 4,329 | 84,576 (0%) | 0% | 1.5 | 6,623 | Common Stock |
| Taylor Sandison | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.53 per share. | 13 Mar 2023 | 7,203 | 288,550 (0%) | 0% | 1.5 | 11,021 | Common Stock |
| Preetam Shah | CFO & CBO | 13 Mar 2023 | 6,648 | 148,141 (0%) | 0% | 1.5 | 10,171 | Common Stock | |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.53 per share. | 13 Mar 2023 | 7,562 | 190,179 (0%) | 0% | 1.5 | 11,570 | Common Stock |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.20 per share. | 12 Jan 2023 | 11,814 | 1,484 (0%) | 0% | 1.2 | 14,177 | Common Stock |
| Preetam Shah | CFO & CBO | 15 Sep 2022 | 50,000 | 0 | - | - | Restricted Stock Unit | ||
| Preetam Shah | CFO & CBO | 15 Sep 2022 | 15,642 | 150,789 (0%) | 0% | 0.8 | 12,035 | Common Stock | |
| Preetam Shah | CFO & CBO | 15 Sep 2022 | 50,000 | 166,431 (0%) | 0% | 0 | Common Stock | ||
| Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 12 Sep 2022 | 16,199 | 221,099 (0%) | 0% | 0.7 | 11,095 | Common Stock |
| Taylor Sandison | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 12 Sep 2022 | 18,478 | 291,753 (0%) | 0% | 0.7 | 12,656 | Common Stock |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 12 Sep 2022 | 18,159 | 193,741 (0%) | 0% | 0.7 | 12,437 | Common Stock |
| Daniel D. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Bonnie L. Bassler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| David L. Gollaher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Carin Canale-Theakston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 31 Mar 2022 | 140,985 | 922,635 (2%) | 0% | 0.8 | 117,018 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 330,000 | 330,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 408,742 | 1,063,620 (2%) | 1% | 0 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 165,000 | 654,878 (1%) | 0% | 0 | Common Stock | |
| Shane M. Ward | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 69,027 | 104,027 (0%) | 0% | 0 | Common Stock | |
| Shane M. Ward | CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 31 Mar 2022 | 23,122 | 80,905 (0%) | 0% | 0.8 | 19,191 | Common Stock |
| Shane M. Ward | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 35,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| Shane M. Ward | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 70,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 50,000 | 237,298 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 50,000 | 306,231 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Brady Johnson | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 20,000 | 20,000 | - | - | Employee Stock Option (right to buy) | |
| Brady Johnson | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 10,000 | 59,366 (0%) | 0% | 0 | Common Stock | |
| Preetam Shah | CFO & CBO | 31 Mar 2022 | 66,001 | 137,251 (0%) | 0% | 0 | Common Stock | ||
| Preetam Shah | CFO & CBO | 31 Mar 2022 | 51,250 | 71,250 (0%) | 0% | 0 | Common Stock | ||
| Preetam Shah | CFO & CBO | 31 Mar 2022 | 24,820 | 112,431 (0%) | 0% | 0.8 | 20,601 | Common Stock | |
| Preetam Shah | CFO & CBO | 31 Mar 2022 | 102,500 | 102,500 | - | - | Employee Stock Option (right to buy) | ||
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 105,000 | 105,000 | - | - | Employee Stock Option (right to buy) | |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 52,500 | 207,900 (0%) | 0% | 0 | Common Stock | |
| Brady Johnson | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 21 Mar 2022 | 654 | 49,366 (0%) | 0% | 0.8 | 530 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.59 per share. | 12 Nov 2021 | 50,000 | 465,878 (1%) | 0% | 1.6 | 79,530 | Common Stock |
| Preetam Shah | CFO & CBO | 12 Nov 2021 | 20,000 | 20,000 (0%) | 0% | 1.5 | 30,800 | Common Stock | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 132,000 | 182,531 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 150,600 | 236,631 (0%) | 0% | 0 | Common Stock | |
| Brady Johnson | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 20,750 | 47,119 (0%) | 0% | 0 | Common Stock | |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 148,000 | 150,551 (0%) | 0% | 0 | Common Stock | |
| Timothy R. Franson | Director | Purchase of securities on an exchange or from another person at price $ 2.12 per share. | 13 Sep 2021 | 7,000 | 11,000 (0%) | 0% | 2.1 | 14,823 | Common Stock |
| Preetam Shah | CFO & CBO | 01 Sep 2021 | 50,000 | 50,000 | - | - | Restricted Stock Unit | ||
| Preetam Shah | CFO & CBO | 01 Sep 2021 | 311,850 | 311,850 | - | - | Stock Option (right to buy) | ||
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 18 Aug 2021 | 10,000 | 415,878 (1%) | 0% | 1.8 | 17,871 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 18 Aug 2021 | 40,000 | 405,878 (1%) | 0% | 1.7 | 68,884 | Common Stock |
| Daniel D. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Bonnie L. Bassler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| David L. Gollaher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Carin Canale-Theakston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 10,000 | 361,878 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 700 | 82,031 (0%) | 0% | 0 | Common Stock | |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 525,000 | 525,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 145,000 | 145,000 | - | - | Employee Stock Option (right to buy) | |
| Jessica Oien | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Bonnie L. Bassler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Carin Canale-Theakston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 05 Jan 2021 | 2,868 | 49,724 (0%) | 0% | 2.1 | 5,908 | Common Stock |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2021 | 1,400 | 51,124 (0%) | 0% | 0 | Common Stock | |
| Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.66 per share. | 05 Jan 2021 | 593 | 50,531 (0%) | 0% | 2.7 | 1,577 | Common Stock |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2021 | 3,500 | 58,940 (0%) | 0% | 0 | Common Stock | |
| Neil Abdollahian | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 05 Jan 2021 | 2,868 | 55,440 (0%) | 0% | 2.1 | 5,908 | Common Stock |
| Neil Abdollahian | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 2.66 per share. | 05 Jan 2021 | 1,469 | 57,471 (0%) | 0% | 2.7 | 3,908 | Common Stock |
| Jessica Oien | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 05 Jan 2021 | 824 | 6,141 (0%) | 0% | 2.1 | 1,697 | Common Stock |
| Jessica Oien | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 2.66 per share. | 05 Jan 2021 | 1,177 | 7,764 (0%) | 0% | 2.7 | 3,131 | Common Stock |
| Jessica Oien | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2021 | 2,800 | 8,941 (0%) | 0% | 0 | Common Stock | |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.01 per share. | 10 Nov 2020 | 50,000 | 50,000 (0%) | 0% | 2.0 | 100,720 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 10 Nov 2020 | 50,000 | 347,878 (0%) | 0% | 2.0 | 100,015 | Common Stock |
| Daniel D. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| David L. Gollaher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| James E. Levine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2020 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 25,000 | 61,891 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 330,000 | 330,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 115,000 | 115,000 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 145,000 | 145,000 | - | - | Employee Stock Option (right to buy) | |
| Jessica Oien | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2020 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | 29 Jan 2020 | 32,283 | 257,902 (0%) | 0% | 2.5 | 81,030 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | 29 Jan 2020 | 32,283 | 0 | - | - | Subscription Rights (right to buy) | ||
| Jeffrey Stein | Director, President & CEO | 29 Jan 2020 | 7,558 | 0 | - | - | Subscription Rights (right to buy) | ||
| Jeffrey Stein | Director, President & CEO | 29 Jan 2020 | 7,558 | 293,878 (0%) | 0% | 2.5 | 18,971 | Common Stock | |
| James E. Levine | Chief Financial Officer | 28 Jan 2020 | 6,891 | 0 | - | - | Subscription Rights (right to buy) | ||
| James E. Levine | Chief Financial Officer | 28 Jan 2020 | 6,891 | 211,891 (0%) | 0% | 2.5 | 17,296 | Common Stock | |
| Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 3.42 per share. | 03 Jan 2020 | 940 | 52,592 (0%) | 0% | 3.4 | 3,215 | Common Stock |
| Neil Abdollahian | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 3.42 per share. | 03 Jan 2020 | 940 | 50,308 (0%) | 0% | 3.4 | 3,215 | Common Stock |
| Jessica Oien | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 3.86 per share. | 02 Jan 2020 | 834 | 6,965 (0%) | 0% | 3.9 | 3,219 | Common Stock |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 33,333 | 33,333 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 17,125 | 17,125 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 50,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 25,688 | 0 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 4,074 | 4,074 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 32,592 | 32,592 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 55,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 29,629 | 29,629 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 9,721 | 9,721 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 56,945 | 56,945 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 100,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 3,704 | 3,704 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 50,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 4,075 | 4,075 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 55,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 13,333 | 13,333 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 20,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 3,333 | 3,333 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 5,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 12,667 | 12,667 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2019 | 19,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2019 | 32,592 | 32,592 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 02 Oct 2019 | 3,295 | 55,872 (0%) | 0% | 1.9 | 6,195 | Common Stock |
| Neil Abdollahian | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 01 Oct 2019 | 7,284 | 49,588 (0%) | 0% | 2.0 | 14,422 | Common Stock |
| Jessica Oien | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 1.86 per share. | 27 Sep 2019 | 1,001 | 7,799 (0%) | 0% | 1.9 | 1,862 | Common Stock |
| James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 24 Sep 2019 | 30,000 | 30,000 (0%) | 0% | 1.9 | 57,240 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 24 Sep 2019 | 52,500 | 225,619 (0%) | 0% | 1.9 | 100,102 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 10,000 | 50,000 | - | - | Restricted Stock Unit | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 10,000 | 282,320 (0%) | 0% | 0 | Common Stock | |
| Paul Daruwala | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 2,100 | 11,900 | - | - | Restricted Stock Unit | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 7,500 | 57,067 (0%) | 0% | 0 | Common Stock | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 2,100 | 59,167 (0%) | 0% | 0 | Common Stock | |
| Paul Daruwala | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 7,500 | 17,500 | - | - | Restricted Stock Unit | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 4,900 | 56,872 (0%) | 0% | 0 | Common Stock | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 17,500 | 51,972 (0%) | 0% | 0 | Common Stock | |
| Neil Abdollahian | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 4,900 | 9,100 | - | - | Restricted Stock Unit | |
| Neil Abdollahian | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 17,500 | 7,500 | - | - | Restricted Stock Unit | |
| Taylor Sandison | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 2,500 | 22,500 | - | - | Restricted Stock Unit | |
| Taylor Sandison | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 1,400 | 12,600 | - | - | Restricted Stock Unit | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 1,400 | 58,622 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 2,500 | 57,222 (0%) | 0% | 0 | Common Stock | |
| Jessica Oien | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2019 | 2,800 | 8,800 (0%) | 0% | 0 | Common Stock | |
| Jessica Oien | General Counsel & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2019 | 2,800 | 11,200 | - | - | Restricted Stock Unit | |
| Daniel D. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| David L. Gollaher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2019 | 265,000 | 265,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2019 | 77,000 | 77,000 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2019 | 77,000 | 77,000 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2019 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | |
| Jessica Oien | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2019 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 2.44 per share. | 08 Mar 2019 | 2,300 | 30,472 (0%) | 0% | 2.4 | 5,612 | Common Stock |
| Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.55 per share. | 07 Mar 2019 | 2,240 | 49,567 (0%) | 0% | 2.6 | 5,714 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2019 | 10,670 | 15,709 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2019 | 21,340 | 173,119 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2019 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Paul Daruwala | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2019 | 14,000 | 14,000 | - | - | Restricted Stock Unit | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 6,000 | 51,807 (0%) | 0% | 0 | Common Stock | |
| Neil Abdollahian | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2019 | 14,000 | 14,000 | - | - | Restricted Stock Unit | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 6,000 | 32,772 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 6,000 | 50,722 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2019 | 14,000 | 14,000 | - | - | Restricted Stock Unit | |
| Jessica Oien | General Counsel & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2019 | 14,000 | 14,000 | - | - | Restricted Stock Unit | |
| Jessica Oien | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2019 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2018 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2018 | 4,619 | 5,039 (0%) | 0% | 0 | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2018 | 9,238 | 194,459 (0%) | 0% | 0 | Common Stock | |
| Brady Johnson | Dir. of Finance & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2018 | 4,000 | 4,000 | - | - | Stock Option (Right to Buy) | |
| David L. Gollaher | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2018 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Daniel D. Burgess | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott M. Rocklage | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Chrysa Mineo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2018 | 250,000 | 250,000 | - | - | Warrant (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 4.70 per share. | 23 May 2018 | 212,766 | 268,320 (1%) | 0% | 4.7 | 1,000,000 | Common Stock |
| Matthew W. Onaitis | Gnrl Counsel, CFO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 72,000 | 72,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 235,000 | 235,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 72,000 | 72,000 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 70,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 70,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Chrysa Mineo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Matthew W. Onaitis | Gnrl Counsel, CFO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2017 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Matthew W. Onaitis | Gnrl Counsel, CFO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2017 | 15,000 | 15,872 (0%) | 0% | 0 | Common Stock | |
| Paul Daruwala | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2017 | 15,000 | 45,807 (0%) | 0% | 0 | Common Stock | |
| Paul Daruwala | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2017 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Marc J.S. Wilson | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2017 | 5,000 | 10,356 (0%) | 0% | 0 | Common Stock | |
| Marc J.S. Wilson | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2017 | 10,000 | 10,000 | - | - | Restricted Stock Unit | |
| Neil Abdollahian | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2017 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2017 | 15,000 | 20,421 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2017 | 15,000 | 40,695 (0%) | 0% | 0 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2017 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 6.79 per share. | 12 Sep 2017 | 7,350 | 51,851 (0%) | 0% | 6.8 | 49,907 | Common Stock |
| Daniel D. Burgess | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott M. Rocklage | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 5.90 per share. | 06 Jun 2017 | 19,344 | 25,695 (0%) | 0% | 5.9 | 114,130 | Common Stock |
| Taylor Sandison | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 5.90 per share. | 06 Jun 2017 | 656 | 6,351 (0%) | 0% | 5.9 | 3,870 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 5.95 per share. | 05 Jun 2017 | 15,000 | 44,501 (0%) | 0% | 5.9 | 89,211 | Common Stock |
| Matthew W. Onaitis | Gnrl Counsel, CFO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 55,000 | 55,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 7.75 per share. | 31 Mar 2017 | 12,900 | 27,196 (0%) | 0% | 7.8 | 99,975 | Common Stock |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| Kenneth Bartizal | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Kevin Forrest | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 7.75 per share. | 31 Mar 2017 | 12,500 | 72,354 (0%) | 0% | 7.8 | 96,875 | Common Stock |
| Kevin Forrest | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Paul Daruwala | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 55,000 | 55,000 | - | - | Employee Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Taylor Sandison | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 55,000 | 55,000 | - | - | Employee Stock Option (right to buy) | |
| Matthew W. Onaitis | Gnrl Counsel, CFO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Neil Abdollahian | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Daniel D. Burgess | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2016 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2016 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Scott M. Rocklage | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2016 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2016 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2016 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 May 2016 | 4,310 | 203,697 | - | - | Common Stock | |
| Kevin Forrest | COO & CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 May 2016 | 4,356 | 58,253 | - | - | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 159,000 | 159,000 | - | - | Stock Option (right to buy) | |
| Kenneth Bartizal | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Kevin Forrest | COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Paul Daruwala | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Dirk Thye | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Marc J.S. Wilson | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 25,000 | 25,000 | - | - | Employee Stock Option (right to buy) | |
| Marc J.S. Wilson | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2016 | 12,000 | 12,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 24 Nov 2015 | 1,300 | 6,700 | - | - | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 24 Nov 2015 | 5,400 | 5,400 | - | - | Common Stock | |
| Kevin Forrest | COO & CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Nov 2015 | 7,087 | 51,719 | - | - | Common Stock | |
| Daniel D. Burgess | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2015 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2015 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Scott M. Rocklage | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2015 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Theodore R. Schroeder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2015 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Timothy R. Franson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2015 | 9,000 | 9,000 | - | - | Stock Option (right to buy) | |
| Daniel D. Burgess | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 3,000 | 3,000 | - | - | Common Stock | |
| Robert J. Perez | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 5,000 | 5,000 | - | - | Common Stock | |
| Scott M. Rocklage | Director, Ten Percent Owner | 20 Apr 2015 | 1,764,195 | 1,956,099 | - | - | Common Stock | ||
| Scott M. Rocklage | Director, Ten Percent Owner | 20 Apr 2015 | 1,764,195 | 0 | - | - | Convertible Preferred Stock | ||
| Scott M. Rocklage | Director, Ten Percent Owner | 20 Apr 2015 | 45,467 | 50,412 | - | - | Common Stock | ||
| Scott M. Rocklage | Director, Ten Percent Owner | 20 Apr 2015 | 45,467 | 0 | - | - | Convertible Preferred Stock | ||
| Patrick J. Heron | None | 20 Apr 2015 | 865,590 | 0 | - | - | Convertible Preferred Stock | ||
| Patrick J. Heron | None | 20 Apr 2015 | 246,668 | 291,023 | - | - | Common Stock | ||
| Patrick J. Heron | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 44,355 | 44,355 | - | - | Common Stock | |
| Patrick J. Heron | None | 20 Apr 2015 | 246,668 | 0 | - | - | Convertible Preferred Stock | ||
| Patrick J. Heron | None | 20 Apr 2015 | 865,590 | 1,021,235 | - | - | Common Stock | ||
| Patrick J. Heron | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 155,645 | 155,645 | - | - | Common Stock | |
| Steven A. Elms | None | 20 Apr 2015 | 8,928,572 | 0 | - | - | Convertible Preferred Stock | ||
| Steven A. Elms | None | 20 Apr 2015 | 351,518 | 351,518 | - | - | Common Stock | ||
| Timothy R. Franson | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 4,000 | 4,000 | - | - | Common Stock | |
| Nina Kjellson | None | 20 Apr 2015 | 1,156,813 | 0 | - | - | Convertible Preferred Stock | ||
| Nina Kjellson | None | 20 Apr 2015 | 1,156,813 | 1,356,813 | - | - | Common Stock | ||
| Nina Kjellson | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 200,000 | 200,000 | - | - | Common Stock | |
| Jeffrey Stein | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Apr 2015 | 420 | 420 | - | - | Common Stock | |
| Taylor Sandison | Chief Medical Officer | 07 Feb 2010 | 4,594 | 67,216 (0%) | 0% | 2.5 | 11,531 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | 07 Feb 2010 | 6,115 | 73,331 (0%) | 0% | 2.5 | 15,349 | Common Stock | |
| Taylor Sandison | Chief Medical Officer | 07 Feb 2010 | 4,594 | 0 | - | - | Subscription Rights (right to buy) | ||
| Taylor Sandison | Chief Medical Officer | 07 Feb 2010 | 6,115 | 0 | - | - | Subscription Rights (right to buy) |